Phase I/II Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

Trial Profile

Phase I/II Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Bendamustine (Primary) ; Ixazomib (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
    • 07 Jun 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
    • 06 Jun 2017 Results (As of Jan 2017, the phase I portion is complete (n= 15)) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top